In this multicenter, randomized, single-blind, placebo-controlled parallel group phase IIa trial conducted in obese patients of either sex with poorly controlled Type 2 diabetes patients on metformin monotherapy using GSK1070806, although it was well tolerated, IL-18 inhibition did not improve glucose control (218). The gene discussed is IL18; the disease is type 2 diabetes mellitus.